Novartis Pharma Schweiz AG
Novartis Pharma Schweiz AG is a Originators company based in Risch-Rotkreuz (Zug) recorded by Swissmedic as the authorisation holder for 130 human medicines. That places it 9 of 334 authorisation holders in Switzerland. Its portfolio is concentrated in Synthetika.
Key facts
| Sector | Originators |
|---|---|
| City | Risch-Rotkreuz |
| Canton | Zug |
| Authorisation holder | Yes |
| Medicines | 130 |
| Founded | Not available |
| Employees | 201-1000 |
| Parent group | Novartis AG |
| Activity | Not available |
| Website | novartis.ch |
Medicines authorised in Switzerland
Novartis Pharma Schweiz AG is recorded by Swissmedic as the authorisation holder for 130 human medicines. The table shows 48 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
48 of 130 authorisations
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Afinitor 5 mg | 59174 | A | L01XE10 | 2009-11-17 |
| Aimovig 70 mg/ml | 66620 | B | - | 2018-07-13 |
| Aimovig 70 mg/ml | 66748 | B | N02CD01 | 2018-07-13 |
| Atectura Breezhaler 150/80 μg | 67597 | B | R03AK14 | 2020-09-10 |
| Azarga | 59179 | B | S01ED51 | 2009-03-25 |
| Azopt | 55236 | B | S01EC04 | 1999-12-17 |
| Beovu 120mg/ml | 67244 | B | S01LA06 | 2020-01-16 |
| Beovu 120mg/ml | 67245 | B | - | 2020-01-16 |
| Certican 0.25 mg | 56239 | B | L04AA18 | 2005-04-21 |
| Certican 0.5 mg | 56238 | B | L04AA18 | 2005-04-21 |
| Ciloxan | 51898 | A | S01AX13 | 1993-06-24 |
| Ciloxan | 55982 | A | S01AX13 | 2003-03-25 |
| Ciproxin HC | 54807 | B | S02CA03 | 1998-12-22 |
| Co-Diovan 80/12 | 54470 | B | C09DA03 | 1998-01-28 |
| Cosentyx 150 mg | 63295 | B | L04AC10 | 2015-02-20 |
| Cosentyx 150 mg / 1 ml | 65225 | B | L04AC10 | 2015-02-20 |
| Cosentyx SensoReady 150 mg / 1 ml | 65226 | B | L04AC10 | 2015-02-20 |
| Cosentyx UnoReady 300 mg / 2 ml | 68324 | B | L04AC10 | 2022-02-03 |
| Diovan 80 mg | 55743 | B | C09CA03 | 2001-03-23 |
| Duotrav | 57615 | B | S01ED51 | 2006-11-30 |
| Enerzair Breezhaler 150/50/160 μg | 67596 | B | R03AL12 | 2020-09-24 |
| Entresto 50 mg | 65673 | B | C09DX04 | 2015-09-17 |
| Entresto 6 mg/6 mg | 69255 | B | C09DX04 | 2024-08-21 |
| Exelon 1 | 54275 | B | N06DA03 | 1997-07-31 |
| Exelon 2 mg/ml | 55051 | B | N06DA03 | 1999-06-04 |
| Exelon Patch 5 | 58078 | B | N06DA03 | 2007-12-20 |
| Exforge 5/80 mg | 57771 | B | C09DB01 | 2006-12-22 |
| Exforge HCT 5 mg/160 mg/12.5 mg | 59407 | B | C09DX01 | 2009-09-16 |
| Exjade 125 mg | 57466 | B | V03AC03 | 2005-11-03 |
| Fabhalta 200 mg | 68603 | A | L04AJ08 | 2024-08-29 |
| Femara 2.5 mg | 54018 | B | L02BG04 | 1997-02-26 |
| Galvumet 50/500 | 58451 | B | A10BD08 | 2009-11-06 |
| Galvus 50 mg | 57834 | B | A10BH02 | 2008-04-30 |
| Gilenya 0.5 mg | 60916 | B | L04AE01 | 2011-01-03 |
| Glivec 100 mg | 56395 | A | L01EA01 | 2003-09-24 |
| Glivec GIST 100 mg | 65814 | A | L01EA01 | 2015-10-20 |
| Ilaris | 66191 | A | L04AC08 | 2017-05-15 |
| Ilaris 150 mg/ml | 70040 | A | L04AC08 | 2025-12-04 |
| Jadenu 90 mg | 65867 | B | V03AC03 | 2017-01-12 |
| Jakavi 5 mg | 62126 | A | L01EJ01 | 2012-12-27 |
| Jakavi 5 mg/ml | 69722 | A | L01EJ01 | 2025-03-27 |
| Kesimpta | 67757 | B | - | 2021-02-01 |
| Kesimpta | 67758 | B | L04AG12 | 2021-02-01 |
| Kisqali 200 mg | 66377 | A | L01EF02 | 2017-10-24 |
| Kymriah | 66778 | A | L01XL04 | 2018-10-18 |
| Lamisil 125 mg | 51306 | B | D01BA02 | 1991-08-27 |
| Lampren 50 mg | 34914 | B | - | 1969-04-24 |
| Leqvio Injektionslösung | 67836 | B | C10AX16 | 2021-09-09 |
Frequently asked questions
How many medicines does Novartis Pharma Schweiz AG have authorised in Switzerland?
Novartis Pharma Schweiz AG is recorded by Swissmedic as the authorisation holder for 130 human medicines (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is Novartis Pharma Schweiz AG based?
The Swiss location recorded for Novartis Pharma Schweiz AG is Risch-Rotkreuz, Zug.
Is Novartis Pharma Schweiz AG a Swissmedic authorisation holder?
Yes. Novartis Pharma Schweiz AG appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.